Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α-Radioimmunotherapy Applications
Citations Over TimeTop 10% of 2011 papers
Abstract
A new bifunctional ligand 3p-C-DEPA was synthesized and evaluated for use in targeted α-radioimmunotherapy. 3p-C-DEPA was efficiently prepared via regiospecific ring opening of an aziridinium ion and conjugated with trastuzumab. The 3p-C-DEPA-trastuzumab conjugate was extremely rapid in binding (205/6)Bi, and the corresponding (205/6)Bi-3p-C-DEPA-trastuzumab complex was stable in human serum. Biodistribution studies were performed to evaluate in vivo stability and tumor targeting of (205/6)Bi-3p-C-DEPA-trastuzumab conjugate in tumor bearing athymic mice. (205/6)Bi-3p-C-DEPA-trastuzumab conjugate displayed excellent in vivo stability and targeting as evidenced by low organ uptake and high tumor uptake. The results of the in vitro and in vivo studies indicate that 3p-C-DEPA is a promising chelator for radioimmunotherapy of (212)Bi and (213)Bi.
Related Papers
- → Clinical radioimmunotherapy—the role of radiobiology(2011)237 cited
- → Mechanisms of Trastuzumab Resistance and Their Clinical Implications(2005)74 cited
- → Response to Radioimmunotherapy Correlates with TumorpO2Measured by EPR Oximetry in Human Tumor Xenografts(2001)38 cited
- → Is there any cumulative dose for trastuzumab?(2014)3 cited
- Advances in monoclonal antibodies for radioimmunotherapy(2002)